Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBCBS Nebraska aqueous shunts stents Coverage | Ope…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - NebraskaPolicy M.53

    MA Aqueous Shunts and Stents for Glaucoma (Preauthorization Required)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Nebraska Policy M.53 alerts

    Get alerted when Policy M.53 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing preauthorization, medical necessity, and coverage stance for FDA‑approved ab externo aqueous shunts and ab interno aqueous stents used to lower intraocular pressure in individuals with glaucoma; applies to Blue Cross Blue Shield - Nebraska members.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA Aqueous Shunts and Stents for Glaucoma (Preauthorization Required)
    Policy CodePolicy M.53
    Change TypeNo material change
    Effective DateMay 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateNov 4, 2026
    Key ActionObtain preauthorization and document failed adequate medical therapy when requesting aqueous shunt or standalone stent implantation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ab externo & ab internodevice approaches described

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1–2
    ab interno stents allowed with cataract surgery
    10%/yrapprox device annual failure rate
    Multipleprocedure & implant codes listed
    ~40references cited
    2026copyright year

    Coverage Criteria for Aqueous Shunts and Stents

    Ab externo aqueous shunts (medical necessity)

    Covered when ALL of the following are met

    Ab externo shunt criteria: Insertion of ab externo aqueous shunts approved by the U.S. Food and Drug Administration may be considered reasonable and necessary as a method to reduce intraocular pressure in individuals with glaucoma where medical therapy has failed to adequately control intraocular pressure.

    From policy section I

    Ab externo aqueous shunts (not covered)

    Ab externo not medically necessary: Use of an ab externo aqueous shunt for all other conditions, including individuals with glaucoma when intraocular pressure is adequately controlled by medications, is considered not reasonable and necessary.

    From policy section II

    Ab interno aqueous stents (standalone)

    Covered when ALL of the following are met

    Ab interno standalone criteria: Insertion of ab interno aqueous stents approved by the U.S. Food and Drug Administration as a method to reduce intraocular pressure in individuals with glaucoma where medical therapy has failed to adequately control intraocular pressure may be considered reasonable and necessary.

    From policy section III

    Ab interno stents with cataract surgery

    Ab interno with cataract criteria: Implantation of 1 or 2 U.S. Food and Drug Administration-approved ab interno stents in conjunction with cataract surgery may be considered reasonable and necessary in individuals with mild-to-moderate open-angle glaucoma treated with ocular hypotensive medication.1 or 2 stents

    From policy section IV

    Ab interno stents (not covered)

    Ab interno not medically necessary: Use of ab interno stents for all other conditions is considered not reasonable and necessary because the effectiveness of this procedure has not been established.

    From policy section V

    Use of ab externo or ab interno aqueous drainage devices for indications other than those specifically listed in this policy is considered outside the scope of coverage. Specifically, insertion of these devices when the member's intraocular pressure (IOP) is already adequately controlled with medical therapy is not considered reasonable and necessary. Requests for devices or procedures that do not meet the policy's stated clinical criteria (for example, situations that are not FDA‑approved indications or are not described in the coverage sections) should be expected to be denied as not medically necessary.

    These Medical Policies are intended to guide benefit administration but do not constitute authorization, certification, or a contract for benefits. Coverage determinations remain subject to the specific terms and conditions of the applicable benefit contract; following this policy does not guarantee payment or authorization for a requested service.

    When intraocular pressure is adequately controlled with medications, the use of an ab externo aqueous shunt is considered not reasonable and necessary and therefore not covered. By contrast, ab interno stents may be considered when used in the circumstances described in this policy (for example, implantation of 1 or 2 stents in conjunction with cataract surgery for qualifying patients); other uses of ab interno stents that fall outside the stated criteria (including non‑FDA‑approved indications) are also considered not reasonable and necessary.

    Procedure and Implant Coding

    Covered CPT CodesCPTCovered
    0253TINSERT ANT SGM DRAINAGE DEV W/O RESERVR INT APPR — Insertion of anterior segment aqueous drainage device, without extraocular reservoir, internal approach, into the suprachoroidal space
    0449TINSJ AQUEOUS DRAIN DEV W/O EO RSVR INITIAL DEV — INSERTION OF AQUEOUS DRAINAGE DEVICE, WITHOUT EXTRAOCULAR RESERVOIR, INTERNAL APPROACH, INTO THE SUBCONJUNCTIVAL SPACE; INITIAL DEVICE
    0450TINSJ AQUEOUS DRAIN DEV W/O EO RSVR EACH ADDL DEV — INSERTION OF AQUEOUS DRAINAGE DEVICE, WITHOUT EXTRAOCULAR RESERVOIR, INTERNAL APPROACH, INTO THE SUBCONJUNCTIVAL SPACE; EACH ADDITIONAL DEVICE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)
    0474TINSJ ANT SEG AQUEOUS DRG DEV W/IO RSVR — INSERTION OF ANTERIOR SEGMENT AQUEOUS DRAINAGE DEVICE, WITH CREATION OF INTRAOCULAR RESERVOIR, INTERNAL APPROACH, INTO THE SUPRACILIARY SPACE
    0671TINSJ ANT SGM DRG DEV TRAB MW W/O RES&CTRC RMVL1+ — Insertion of anterior segment aqueous drainage device into the trabecular meshwork, without external reservoir, and without concomitant cataract removal, one or more
    66179AQUEOUS SHUNT EXTRAOCULAR RESERVOIR W/O GRAFT — AQUEOUS SHUNT TO EXTRAOCULAR EQUATORIAL PLATE RESERVOIR, EXTERNAL APPROACH; WITHOUT GRAFT
    66180AQUEOUS SHUNT EXTRAOC EQUAT PLATE RSVR W/GRAFT — AQUEOUS SHUNT TO EXTRAOCULAR EQUATORIAL PLATE RESERVOIR, EXTERNAL APPROACH; WITH GRAFT
    66183INSERT ANTER DRAINAGE DEV W/O EXTRAOC RESERVOIR — Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external approach
    66184REVJ SHUNT EXTRAOCULAR RESERVOIR W/O GRAFT — REVISION OF AQUEOUS SHUNT TO EXTRAOCULAR EQUATORIAL PLATE RESERVOIR; WITHOUT GRAFT
    66185REVJ AQUEOUS SHUNT EXTRAOCULAR RESERVOIR W/GRAFT — Revision of aqueous shunt to extraocular equatorial plate reservoir; with graft
    Covered HCPCS Codes (implants)HCPCSCovered
    C1783Ocular imp, aqueous drain de — Ocular implant, aqueous drainage assist device
    L8612Aqueous shunt prosthesis — Aqueous shunt
    Referenced coding systemmixed
    CPTDocument references CPT codes; Current Procedural Terminology (CPT) is copyright American Medical Association.

    Provider Actions, Documentation, and Authorization Requirements

    Prior Authorization

    Preauthorization required for aqueous shunts and stents

    Preauthorization is required for aqueous shunts and stents; requests must demonstrate that the indications meet the policy's medical necessity criteria (for example, failed medical therapy or specified use with cataract surgery).

    • Include documentation showing that the patient meets the clinical criteria in the policy (e.g., medical therapy has failed to adequately control IOP or device is being implanted with cataract surgery where allowed).
    Prior Authorization

    Policy M.53: Preauthorization Required

    Medical Policy M.53 is designated 'Preauthorization Required' for aqueous shunts and stents for glaucoma; obtain authorization per plan procedures before scheduling the procedure.

    Background on Glaucoma and Device Approaches

    Glaucoma is a progressive optic neuropathy typically associated with elevated intraocular pressure (IOP) due to impaired aqueous humor outflow, leading to progressive visual field loss if untreated. Surgical approaches aim to lower IOP by improving aqueous outflow and include ab externo aqueous shunts—devices implanted via an external approach to divert fluid to an external reservoir or space—and ab interno aqueous stents—intraocular implants placed via an internal approach to bypass the trabecular meshwork or access alternative outflow pathways. The policy distinguishes these approaches by indication and evidence: ab externo shunts and standalone ab interno stents may be reasonable when medical therapy has failed to adequately control IOP, while implantation of 1 or 2 ab interno stents at the time of cataract surgery is addressed separately for mild‑to‑moderate open‑angle glaucoma.

    Definitions of Devices and Procedures

    inv-23: ab externo aqueous shunt — definition and typical surgical approach
    DefinitionA surgically implanted device placed via an external approach to shunt aqueous humor, often to an external reservoir or the suprachoroidal space (examples: Ahmed, Baerveldt, Molteno, EX-PRESS).
    Typical surgical approachExternal (ab externo) placement with creation of an external reservoir or plate and tubing that diverts aqueous from the anterior chamber to the reservoir or suprachoroidal space.
    Primary indicationFailed medical or prior surgical therapy to control intraocular pressure — used to reduce IOP when medical therapy has failed.
    Comparative outcomes/risksGenerally lower risk of hypotony compared with trabeculectomy but usually inferior IOP outcomes versus guarded filtration surgery; complications include corneal endothelial failure and conjunctival erosion; device failure rate ~10% per year.
    Examples (FDA-cleared)Ahmed, Baerveldt, Molteno, EX-PRESS mini-shunt.
    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA Aqueous Shunts and Stents for Glaucoma (Preauthorization Required)
    Policy CodePolicy M.53
    Change TypeNo material change
    Effective DateMay 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateNov 4, 2026
    Key ActionObtain preauthorization and document failed adequate medical therapy when requesting aqueous shunt or standalone stent implantation.
    SourceLink
    On This Page
    Coverage Criteria for Aqueous Shunts and StentsProcedure and Implant CodingProvider Actions, Documentation, and Authorization RequirementsBackground on Glaucoma and Device ApproachesDefinitions of Devices and Procedures
    Step Therapy

    Prior medical therapy must have failed before standalone implantation

    Policy requires documentation of prior adequate medical therapy failure before standalone surgical implantation of ab externo shunts or standalone ab interno stents, except where the policy allows stent implantation concurrently with cataract surgery.

    • For standalone implantation requests, document trials of and insufficient response to ocular hypotensive medications.
    Note

    Provider action: verify authorization and benefit terms

    Provider awareness: follow preauthorization and documentation requirements in this policy when requesting authorization for aqueous shunt or stent procedures.

    • Policies do not guarantee coverage; benefit determination is by the member's benefit contract.
    Documentation Required

    Document clinical necessity and failed medical therapy

    Documentation submitted with the authorization request should support that medical therapy has failed to adequately control intraocular pressure when requesting insertion of ab externo aqueous shunts or standalone ab interno stents.

    • Include records of medication trials, IOP measurements, and clinical notes demonstrating inadequate control despite therapy.
    Documentation Required

    Document cataract‑combined stent procedure details

    When requesting implantation of 1 or 2 ab interno stents with cataract surgery, document that the patient has mild-to-moderate open‑angle glaucoma treated with ocular hypotensive medication and that cataract extraction is planned.

    • Specify number of stents (1 or 2) and that the procedure is being performed in conjunction with cataract surgery.
    Billing Rule

    Provider/billing reminder: follow benefit contract and coding references

    Medical policies reference CPT codes and are used in administering plan benefits; follow the terms of the applicable benefit contract and plan procedures when seeking authorization and submitting claims.

    • Use the CPT/HCPCS codes referenced in the policy when requesting authorization and billing.
    Denial Risk

    Denial risk: ab externo shunt when IOP controlled by medication

    Use of an ab externo aqueous shunt when intraocular pressure is adequately controlled by medications is considered not reasonable and necessary and may be denied.

    Denial Risk

    Denial risk: ab interno stents used outside specified indications

    Use of ab interno stents for conditions other than those specified (for example, not after failed medical therapy or not performed as an adjunct to cataract surgery where indicated) is considered not reasonable and necessary and may be denied.

    Note

    Benefits determination reminder

    Benefits for a particular service or item are determined by the terms and conditions of the applicable benefit contract; the policy does not constitute authorization or a contract for benefits and lack of benefit provision may lead to denial.

    inv-24: ab interno aqueous stent — definition and typical mechanism
    DefinitionAn intraocular device implanted via an internal (ab interno) approach to bypass the trabecular meshwork or to access suprachoroidal or subconjunctival outflow pathways to reduce intraocular pressure.
    Typical mechanismInserted through the cornea and anterior chamber to create a direct conduit for aqueous outflow (e.g., into Schlemm canal, suprachoroidal space, or subconjunctival reservoir), lowering IOP by improving outflow.
    Indications per policyMay be considered reasonable and necessary when FDA‑approved ab interno stents are used to reduce IOP in individuals with glaucoma where medical therapy has failed to adequately control IOP; 1–2 stents may be implanted with cataract surgery for mild-to-moderate open-angle glaucoma on ocular hypotensive medication.
    ExamplesiStent, Hydrus, CyPass (suprachoroidal), XEN gelatin stent.
    inv-25: MIGS / trabecular micro-bypass and gel stents — examples and related devices
    Definition / scopeMIGS encompasses less invasive procedures and devices that improve aqueous outflow, including trabecular micro-bypass stents and gel (subconjunctival) stents used to lower IOP with generally milder risk profiles than traditional filtration surgery.
    Examples — trabecular micro-bypassiStent (1-mm stent inserted into Schlemm canal), Hydrus; typically provide trabecular bypass to improve conventional outflow.
    Examples — gel / subconjunctival stentsXEN gelatin stent (transscleral gelatin stent creating subconjunctival outflow);
    Related devices referencedEX-PRESS filtration device and various suprachoroidal micro-stents; devices are compared in trials and reviews cited in the policy references.